KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,304,588 | +614.9% | 448,701 | +801.0% | 0.00% | – |
Q2 2023 | $2,000,884 | -66.8% | 49,798 | -64.7% | 0.00% | -100.0% |
Q1 2023 | $6,019,420 | -12.3% | 140,970 | -1.4% | 0.00% | 0.0% |
Q4 2022 | $6,864,987 | +196.7% | 142,961 | +132.4% | 0.00% | – |
Q3 2022 | $2,314,000 | -30.1% | 61,521 | -48.6% | 0.00% | – |
Q2 2022 | $3,310,000 | +17.4% | 119,798 | +131.1% | 0.00% | – |
Q1 2022 | $2,819,000 | +576.0% | 51,828 | +625.8% | 0.00% | – |
Q4 2021 | $417,000 | -86.9% | 7,141 | -91.1% | 0.00% | – |
Q3 2021 | $3,173,000 | +225.1% | 80,212 | +249.1% | 0.00% | – |
Q2 2021 | $976,000 | +5322.2% | 22,980 | +7907.0% | 0.00% | – |
Q1 2021 | $18,000 | -99.7% | 287 | -99.6% | 0.00% | -100.0% |
Q4 2020 | $5,336,000 | +22133.3% | 75,635 | +11963.0% | 0.00% | – |
Q3 2020 | $24,000 | -70.4% | 627 | -70.9% | 0.00% | – |
Q2 2020 | $81,000 | – | 2,153 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
Atom Investors LP | 49,981 | $3,526,000 | 0.36% |